Bushra Mohandes

Bushra Mohandes

Auto-generated profile, based on publicly available information

Bushra Mohandes

Department of Visceral Surgery Cantonal Hospital Basel‐Land Liestal Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Journal of Pharmacopuncture
Verified
Journal Article
Open access
PDF file
BMBushra Mohandes
Bushra Mohandes
FBFatma Elsayed Ahmed Bayoumi
Fatma Elsayed Ahmed Bayoumi
AAAisha Abdulkarim AllahDiwaya
Aisha Abdulkarim AllahDiwaya
MFMaryam Salah Falah
Maryam Salah Falah
LALeen Hesham Alhamd
Leen Hesham Alhamd
Muhammad Candragupta JihwapraniMuhammad Candragupta Jihwaprani
Muhammad Candragupta Jihwaprani
Bushra Mohandes, Fatma Elsayed Ahmed Bayoumi, Aisha Abdulkarim AllahDiwaya, Maryam Salah Falah, Leen Hesham Alhamd, Razan Abid Alsawadi, Yipeng Sun, Aidi Ma, Idris Sula, Muhammad Candragupta Jihwaprani. J Pharmacopuncture 2024;27:177-89. https://doi.org/10.3831/KPI.2024.27.3.177

21 May 2026 in The Egyptian Journal of Internal Medicine
Verified
Journal Article
Open access
MFMaryam Falah
Maryam Falah
LALeen Alhamd
Leen Alhamd
FBFatma Bayoumi
Fatma Bayoumi
ADAisha Allah Diwaya
Aisha Allah Diwaya
ETEnas Taha
Enas Taha
FEFathiya El-Raey
Fathiya El-Raey
Background: Mirikizumab, a monoclonal antibody targeting interleukin-23 (IL-23), was studied for adult patients with moderate-to-severe inflammatory bowel disease (IBD). However, conflicting evidence exists on its safety, efficacy and optimal dosing strategy. Aim: To evaluate the safety and efficacy of mirikizumab in treating IBD and understand a dose–response relationship based on clinical, endoscopic, and histological outcomes. Methodology: A systematic search of six electronic databases, i.e. PubMed, ClinicalTrials.gov, Cochrane CENTRAL, ScienceDirect, ProQuest, and EBSCO, was conducted (PROSPERO: CRD42024570804). Relevant data were extracted from selected studies. Primary endpoints included safety, efficacy, adverse events (AEs), serious adverse events (SAEs), and mortality. Dose–response relationship was assessed as a secondary endpoint. Results: Six trials were eligible from 415 screened records, pooling 3,990 participants (3,073 of whom received mirikizumab). Mirikizumab significantly improved clinical remission (relative risk [RR] [95% CI] = 1.87 [1.57–2.22]) and histological outcomes (RR [95% CI] = 1.63 [1.35–1.97]) with minimal heterogeneity across subgroups, i.e. intravenous (IV) and subcutaneous (SC) routes. The drug significantly improved endoscopic remission (RR [95% CI] = 1.66 [1.28–2.16]), particularly with IV route (RR = 2.09). The risk for AEs was similar between groups, with low heterogeneity (I 2 = 2.0%). Conclusion: Mirikizumab improves clinical, histological, and endoscopic outcomes in IBD with a favorable safety profile. There was no significant difference with different injection routes and with incrementing dose beyond 200 mg.

1 October 2026 in World Journal of Surgery
Verified
Journal Article
Open access
PDF file
ATAnas Taha
Anas Taha
BMBushra Mohandes
Bushra Mohandes
MHMichael Drew Honaker
Michael Drew Honaker
STStephanie Taha‐Mehlitz
Stephanie Taha‐Mehlitz
SRShantanu Roy
Shantanu Roy
PCPhilippe C. Cattin
Philippe C. Cattin
Background: Enhanced recovery after surgery (ERAS) programs optimize perioperative care to reduce surgical stress and improve recovery. Compliance with ERAS pathways is essential for achieving favorable outcomes, yet predictors of adherence remain poorly understood. Using demographic, clinical, and procedural factors, this study aims to develop and validate a predictive model for perioperative compliance within ERAS protocols for colorectal surgery. Methods: A retrospective analysis was performed, including all patients who were managed under the ERAS framework. The compliance model was built based on feature engineering, which involved scaling, polynomial interaction expansion, and Lasso‐based variable selection. Three regression algorithms (CatBoost, XGBoost, and histogram‐based gradient boosting) were compared using ten‐fold cross‐validation. Predictive performance was evaluated by root mean squared error (RMSE) and mean absolute error (MAE). Results: Analysis was performed on 1119 patients who had colorectal surgery under ERAS pathways. The average hospital stay was 9.2 days, and the average operating time was 221.5 minutes. The ERAS compliance rate was 78% overall, with minimally invasive procedures having a higher compliance rate (83%) than open surgery (67%). The CatBoost model had the best performance with good precision. The strongest predictors of compliance, according to feature importance analysis, were surgical approach, ASA class, and operative duration. These were followed by BMI, age, and ERAS process measures such as PONV prophylaxis. Conclusion: The newly developed compliance model will enable early identification of patients at risk of low adherence, thus supporting personalized perioperative management and improved recovery outcomes.